Prior research has revealed poorer clinical outcomes after drug-eluting stent (DES) implantation for hemodialysis patients. This study aims to investigate the long-term clinical and angiographic outcomes after newgeneration DES implantation for hemodialysis patients.
D rug-eluting stents (DES) implantation has emerged as standard therapy for coronary artery disease, and new-generation DES ( e. g. , everolimus-, zotarolimus-, and biolimus-eluting stents) are extensively used around the world. 1) Prior research has revealed the safety and efficacy of the new-generation DES in the routine clinical setting. [1] [2] [3] However, the everolimuseluting stent has failed to demonstrate optimal one-year clinical outcome in hemodialysis patients. 4) Pathophysiology of restenosis specific to dialysis patients may exist. Late restenosis or calcium-phosphate metabolism 5, 6) may be responsible for the poor clinical outcomes in hemodialysis patients.
This study aims to investigate the long-term clinical and angiographic outcomes after new-generation DES implantation for patients on maintenance hemodialysis.
Methods
Of 3,273 patients who underwent percutaneous coronary intervention (PCI) at our institution from January 2010 to March 2016, we retrospectively enrolled 91 consecutive Japanese patients (118 lesions) who underwent successful new-generation DES implantation for the first time. This study protocol was approved by the Institutional Ethics Committee of our institution, which waived the necessity for informed consent in accordance with the Japanese standard ethical policy established by the Ministry of Health, Labour and Welfare. Of note, the observers were blinded to the patient demographics during the analysis of quantitative images.
In this study, the following six types of newgeneration DES were available: Xience V (Abbott Vascular, Santa Clara, CA, USA; 36 lesions in 29 patients) and Promus Element (Boston Scientific, Natick, MA, USA; 50 lesions in 40 patients), Resolute Integrity (Medtronic Vascular, Santa Rosa, CA, USA; 10 lesions in 10 patients), Nobori (Terumo, Tokyo, Japan; 17 lesions in 16 patients), Ultimaster (Terumo; three lesions in three patients), and Synergy (Boston Scientific; two lesions in two patients). Upon requiring the loading of dual antiplatelet drugs, all patients received 300 mg aspirin and 300 mg clopidogrel or 20 mg prasugrel before PCI. First, the patients were administered 100 U/kg body weight heparin just before the PCI procedure. Then, 2,000 units of heparin were administered every hour during PCI. The standard antiplatelet regimen at our institution is 100 mg/ day of aspirin administered indefinitely and thienopyridine (75 mg/day of clopidogrel or 3.75 mg prasugrel) for, at least, 6 months. Furthermore, the duration of dual antiplatelet therapy was at the discretion of each attending physician.
The standard strategy has already been described elsewhere. 7) Briefly, the procedure is as follows: (1) both full-coverage stenting and adequate stent sizing are planned; (2) non-compliant balloon dilation is typically performed to minimize incomplete stent apposition; (3) additional short-stent implantation is performed for stent edge dissection; (4) single stent, as well as provisional kissing balloon technique, is performed for bifurcation lesions, except for those with the Medina classification score of (1,1,1); and (5) an intravascular imaging device (intravascular ultrasound or optical coherence tomography) is used for optimizing the stenting. Else, the selection of adjunctive procedures was at the operator's discretion.
A systematic angiographic follow-up was scheduled at approximately 8-12 months after the new-generation DES implantation with the patients' consent. In addition, the qualitative coronary angiography assessment was performed in accordance with the standard definition, as used previously. 2, 8) Then, quantitative coronary angiography (QCA) was assessed using QAngio XA 7.2 (Medis, Leiden, The Netherlands), and we obtained the baseline, post-procedure, and follow-up data. Besides systematic 8-12-month follow-up angiograms, we analyzed clinically driven angiograms (if performed before the follow-up period) as follow-up data. We defined the target segment as the entire segment comprising the implanted stent and the 5 mm proximal and distal edges adjacent to the stent, as described previously. 9, 10) A segment to be treated with multiple overlapping stents was considered a single target segment. We defined binary restenosis as diameter stenosis ! 50%. We measured serum calcium and phosphorus levels in the blood samples obtained just before dialysis. Furthermore, we corrected the serum calcium level for the albumin level. Per the treatment guidelines for secondary hyperparathyroidism by the Japanese Society of Dialysis Therapy, 11) the incidence of suboptimal (increased) calcium (> 10 mg/dL), phosphorus levels (> 6 mg/dL), and calcium-phosphorus product (> 55 mg 2 /dL 2 ) were also evaluated. As clinical events were followed in July 2017 for all patients, the follow-up period was, at least, 1.5 years. In this study, the primary endpoints were major adverse cardiac and cerebrovascular events (MACCE; allcause death, myocardial infarction, and stroke) and clinically driven target lesion revascularization (TLR), defined as PCI or coronary artery bypass grafting for restenosis with at least one of the following features; typical chest symptom due to coronary ischemia; positive cardiac biomarker; diameter stenosis over 70% by QCA; fractional flow reserve under or equal to 0.8. The secondary endpoint was binary restenosis.
Continuous variables are expressed as mean ± standard deviation and compared using an unpaired t-test or one-way ANOVA. Categorical variables are expressed as frequencies and compared using the χ 2 or Fisher's exact tests. In addition, Kaplan-Meier curve analysis and the log-rank test were performed to test the predictive value of calcium-phosphorus product for MACCE. Using a Cox proportional hazards model, we identified independent predictors of MACCE. We considered P < 0.05 as statistically significant, and all reported P-values were two sided. All statistical analyses were performed using SPSS Statistics 20 (SPSS Inc., Chicago, IL, USA). Table I summarizes the baseline patients' characteristics. The mean age was 65.9 ± 11.0 years. The prevalence of diabetic nephropathy was 68.1%, and the average duration of maintenance hemodialysis was 8.0 ± 7.7 years. The clinical diagnosis was acute coronary syndrome in 40 (44%) patients. Primary endpoints -MACCE and TLR: In this study, MACCE occurred in 36 (39.6%) patients, and 21 (23.1%) died (cardiac: seven; or non-cardiac: 14). TLR was performed in 11 (12.1%) patients and was the major cause of MACCE. In addition, myocardial infarction and stroke occurred in 11 (12.1%) and four (4.4%) patients, respectively.
Results
We categorized all patients into two groups based on the occurrence of MACCE (Table I) . No statistical difference was observed in patients' characteristics between the two groups, except that the prevalence of peripheral artery disease was significantly higher in the MACCE group. Regarding the laboratory data, the serum calcium level was significantly higher in the MACCE group. When the calcium level, phosphorus level, and calcium-phosphorus product were classified depending on the median value, high calcium level was more frequently observed in the MACCE group. The suboptimal calcium-phosphorus product (> 55) was more frequent in the MACCE group, although the difference was not statistically significant. Else, we observed no significant differences in the laboratory data between the two groups. We used the multivariate Cox proportional hazards model to determine independent predictors of MACCE with variables showing a P-value < 0.2 (Table II) . The coexistence of peripheral artery disease, the serum calcium level, and the suboptimal calcium-phosphorus product were the independent predictors of MACCE. The Figure shows that the suboptimal calcium-phosphorus product group exhibited a higher incidence of MACCE. When the patients were divided into two groups based on the TLR, the serum calcium level tended to be higher in the TLR group (9.56 ± 0.97 versus 8.92 ± 0.91 mg/dL; P = 0.059). Furthermore, when the patients were divided into three groups with respect to NEW DRUG-ELUTING STENTS FOR HEMODIALYSIS PATIENTS TLR (+), non-TLR MACCE (+) and MACCE (−), the serum calcium level was the highest in the TLR group (9.56 ± 0.97 versus 9.25 ± 0.90 versus 8.77 ± 0.88 mg/dL, P = 0.01). Secondary endpoint -binary restenosis: Of all patients, 76 (64.4%) lesions of 57 (62.6%) patients received follow-up coronary angiography. The qualitative and quantitative coronary analyses were feasible in all lesions. We observed in-stent binary restenosis in 13 (17.1%) lesions. The mean diameter stenosis before the procedure was 63.5% ± 18.0%, and the mean in-segment and instent late loss were 0.29 ± 0.70 and 0.41 ± 0.71 mm, respectively. On the basis of the binary restenosis in the QCA, we divided all patients into two groups (Table III) . The target vessel tended to exist in the right coronary artery more frequently in the binary restenosis group. The use of Rotablator and imaging modalities did not exhibit any significant difference between both groups. In addition, the qualitative coronary analysis data did not exhibit a significant difference between both groups. Regarding the QCA data, the reference diameter before the index procedure and in-segment diameter stenosis after the index procedure were higher in the binary restenosis group.
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Figure.
Cumulative incidence of major adverse cardiac and cerebrovascular events. The suboptimal calcium-phosphorus product (> 55 mg 2 /dL 2 ) group showed higher incidence of major adverse cardiac and cerebrovascular events (MACCE).
Discussion
Regarding the new-generation DES implantation for hemodialysis patients, this study attained the following results: (1) clinical events remain frequent; (2) high serum calcium and coexistence of peripheral artery disease are markedly associated with MACCE; (3) serum calcium level, suboptimal calcium-phosphorus product, and coexistence of peripheral artery disease were independent predictors of MACCE. The strengths of this study are as follows: (1) an extended follow-up period; (2) exclusive data of new-generation DES for hemodialysis patients; and (3) investigation with the serum calcium and phosphate levels.
To date, the high cardiovascular event rate in patients of maintenance hemodialysis has been widely known.
12)
The long-term follow-up data of this study proved that even new-generation DES is yet to overcome this challenging clinical subset. Thus, more effective innovation in coronary revascularization is warranted to ameliorate the clinical outcome in patients of maintenance hemodialysis. This study highlighted the importance of the optimization of the serum calcium and phosphorus levels. A prior study reported that the serum phosphorus level was a robust predictor of a clinical event after DES implantation in hemodialysis patients. 13) In fact, the guideline addresses the priority of phosphorus optimization in hemodialysis patients. 14) In this study, suboptimal calcium-phosphorus product was an independent predictor of MACCE. In hemodialysis patients, the disorders of calcium homeostasis are associated with cardiovascular events and all-cause mortality. 15) Previous studies have reported a correlation between higher calcium levels and cardiovascular events. 15, 16) Not only phosphorus but also the calcium level may have to be optimized more aggressively after PCI for hemodialysis patients.
In addition, this study indicates that the coexistence of peripheral artery disease is another predictor of a clinical event. Our findings support a previous study that reported that peripheral artery disease is a significant predictor of death after an invasive cardiovascular procedure for hemodialysis patients.
17) The progression of peripheral artery disease is frequent in patients with renal dysfunction and accompanied by the progression of various atherosclerotic diseases in hemodialysis patients. 18, 19) Consequently, the cause of death in hemodialysis patients who underwent coronary intervention is not necessarily cardiac death alone. In addition, hemodialysis patients with peripheral artery disease report polyvascular atherosclerotic disease frequently, which can be linked to myocardial infarction or cerebrovascular diseases, such as stroke or transient ischemic attack. 18) Hence, coronary interventionists should consider performing a comprehensive medical examination on hemodialysis patients to prevent atherosclerotic events.
This study revealed that a larger reference diameter was a predictor of binary restenosis. Typically, smaller vessels tend to exhibit a higher TLR rate. 20) To the best of our knowledge, previous QCA data regarding PCI for hemodialysis patients have not established any correlation between the vessel size and restenosis. 21) This study suggested that a paradox might exist in the association of the vessel size and restenosis, especially in hemodialysis patients. As previous investigation has indicated poorer correlation of angiographic stenosis with fractional flow reserve in hemodialysis patients, 22) hemodynamic character- istics specific to the coronary artery of dialysis patients may exist. Further extensive investigation is warranted. This study has several limitations. First, it was based on a retrospective analysis with a limited sample size. Second, neither platelet activation nor response to thienopyridine ware analyzed, although previous investigation indicated the impact of these factors on clinical events after everolimus-eluting stents implantation for hemodialysis patients. 23) Third, the QCA data might not be real because only 61.5% of the patients received follow-up coronary angiography. Unfortunately, some elderly patients declined, and other patients died before the follow-up period. Hence, further extensive studies with a large sample size are warranted to overcome the limitations of this study and interpret the results in a broader perspective.
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Conclusions
For hemodialysis patients, MACCE after newgeneration DES implantation remains frequent and is associated with high serum calcium and coexistence of peripheral artery disease. When performing PCI for hemodialysis patients, the coronary interventionist might have to pay more attention to the serum calcium level and other atherosclerotic diseases.
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